Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme

Inclusion Criteria:

• Histologically confirmed diagnosis of GBM
• Grade IV GBM tumors that have recurred after total resection
• Age > 18 years
• At least four weeks following any recent surgery
• Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥three months.
• No IV chemotherapy for three weeks prior to treatment under this research protocol andno external beam radiation for four weeks prior to treatment under this researchprotocol.
• Patients must have adequate hematologic reserve
• Pre-enrollment coagulation parameters (PT and PTT) must be adequate.
• Patients must agree to use a medically effective method of contraception during andfor a period of three months after the treatment period. A pregnancy test will beperformed on each premenopausal female of childbearing potential immediately prior toentry into the research study.
• Patients must be able to understand and give written informed consent. Informedconsent must be obtained at the time of patient screening.

Exclusion Criteria:

• Women who are pregnant or lactating.
• Women of childbearing potential and fertile men will be informed as to the potentialrisk of procreation while participating in this research trial and will be advisedthat they must use effective contraception during and for a period of three monthsafter the treatment period.
• Patients with significant intercurrent medical or psychiatric conditions that wouldplace them at increased risk or affect their ability to receive or comply withtreatment or post-treatment clinical monitoring.